MX2009006214A - Moduladores del receptor cb1. - Google Patents
Moduladores del receptor cb1.Info
- Publication number
- MX2009006214A MX2009006214A MX2009006214A MX2009006214A MX2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A MX 2009006214 A MX2009006214 A MX 2009006214A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- tetrazolyl
- cooh
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010033307 Overweight Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cycloalkyi Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625197A GB0625197D0 (en) | 2006-12-18 | 2006-12-18 | Cannabinoid receptor modulators |
| GB0717998A GB0717998D0 (en) | 2007-09-14 | 2007-09-14 | Canabinoid receptor modulators |
| PCT/GB2007/004831 WO2008075012A1 (en) | 2006-12-18 | 2007-12-17 | Cb1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006214A true MX2009006214A (es) | 2009-06-22 |
Family
ID=39156232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006214A MX2009006214A (es) | 2006-12-18 | 2007-12-17 | Moduladores del receptor cb1. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8148404B2 (enExample) |
| EP (2) | EP2121659B1 (enExample) |
| JP (2) | JP5437812B2 (enExample) |
| CN (1) | CN103145620A (enExample) |
| AU (2) | AU2007336061B2 (enExample) |
| BR (1) | BRPI0720732A2 (enExample) |
| CA (2) | CA2673177A1 (enExample) |
| EA (1) | EA017170B1 (enExample) |
| IL (2) | IL198989A0 (enExample) |
| MX (1) | MX2009006214A (enExample) |
| NZ (1) | NZ578063A (enExample) |
| WO (3) | WO2008075012A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US7977358B2 (en) * | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| JP2011506410A (ja) * | 2007-12-10 | 2011-03-03 | ７ティーエム ファーマ エイ／エス | カンナビノイド受容体モジュレーター |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| EP2731561B1 (en) | 2011-07-14 | 2016-03-23 | Cook Medical Technologies LLC | A sling to be used in the treatment of obstructive sleep apnea |
| US9710644B2 (en) | 2012-02-01 | 2017-07-18 | Servicenow, Inc. | Techniques for sharing network security event information |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| WO2014189540A1 (en) | 2012-10-16 | 2014-11-27 | Catalano Peter J | Method and apparatus for treating obstructive sleep apnea (osa) |
| WO2015017749A1 (en) | 2013-08-01 | 2015-02-05 | Mohan P Arun | Tissue adjustment implant |
| AU2014306232B2 (en) | 2013-08-05 | 2018-12-06 | C2Dx, Inc. | Medical devices having a releasable tubular member and methods of using the same |
| EP2898920B1 (en) | 2014-01-24 | 2018-06-06 | Cook Medical Technologies LLC | Articulating balloon catheter |
| US9974563B2 (en) | 2014-05-28 | 2018-05-22 | Cook Medical Technologies Llc | Medical devices having a releasable member and methods of using the same |
| WO2016022454A1 (en) | 2014-08-04 | 2016-02-11 | Darin Schaeffer | Medical devices having a releasable tubular member and methods of using the same |
| AU2018294247A1 (en) | 2017-06-29 | 2020-01-23 | Cook Biotech Incorporated | Implantable medical devices for tissue repositioning |
| JP2021535202A (ja) * | 2018-08-20 | 2021-12-16 | ベッソール ファルマ、エルエルシー | 新規カンナビノイドおよびカンナビノイド酸ならびにそれらの誘導体 |
| CA3166630A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| AU780572B2 (en) | 1999-10-18 | 2005-04-07 | University Of Connecticut, The | Pyrazole derivatives as cannabinoid receptor antagonists |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| ES2272449T3 (es) * | 2000-03-23 | 2007-05-01 | Solvay Pharmaceuticals B.V. | Derivados de 4,5-dihidro-1h-pirazol con actividad antagosnista de cb-1. |
| CA2439152C (en) * | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| EP1421077A4 (en) | 2001-08-31 | 2004-11-17 | Univ Connecticut | NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS |
| FR2831883B1 (fr) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| NZ540515A (en) * | 2002-12-02 | 2008-01-31 | Astellas Pharma Inc | Pyrazole derivatives useful as COX-I inhibitors |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| WO2004099157A1 (en) | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| FR2856683A1 (fr) | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
| BRPI0507786A (pt) | 2004-02-20 | 2007-07-17 | Astrazeneca Ab | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos |
| FR2867685B1 (fr) * | 2004-03-17 | 2008-05-23 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive |
| WO2006067443A1 (en) | 2004-12-23 | 2006-06-29 | Astrazeneca Ab | Therapeutic agents |
| WO2006133926A1 (en) * | 2005-06-17 | 2006-12-21 | Carex Sa | Pyrazole derivates as cannabinoid receptor modulators |
| US7687481B2 (en) * | 2006-03-10 | 2010-03-30 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
-
2007
- 2007-12-17 CN CN2012103916453A patent/CN103145620A/zh active Pending
- 2007-12-17 AU AU2007336061A patent/AU2007336061B2/en not_active Ceased
- 2007-12-17 EP EP07848579.4A patent/EP2121659B1/en not_active Not-in-force
- 2007-12-17 JP JP2009542195A patent/JP5437812B2/ja not_active Expired - Fee Related
- 2007-12-17 CA CA002673177A patent/CA2673177A1/en not_active Abandoned
- 2007-12-17 MX MX2009006214A patent/MX2009006214A/es active IP Right Grant
- 2007-12-17 WO PCT/GB2007/004831 patent/WO2008075012A1/en not_active Ceased
- 2007-12-17 BR BRPI0720732-8A patent/BRPI0720732A2/pt not_active IP Right Cessation
- 2007-12-17 EP EP07848570.3A patent/EP2121617B1/en not_active Not-in-force
- 2007-12-17 US US12/518,446 patent/US8148404B2/en not_active Expired - Fee Related
- 2007-12-17 NZ NZ578063A patent/NZ578063A/en not_active IP Right Cessation
- 2007-12-17 EA EA200900838A patent/EA017170B1/ru not_active IP Right Cessation
- 2007-12-17 US US12/519,432 patent/US8124634B2/en not_active Expired - Fee Related
- 2007-12-17 WO PCT/GB2007/004835 patent/WO2008075013A1/en not_active Ceased
- 2007-12-17 WO PCT/GB2007/004842 patent/WO2008075019A1/en not_active Ceased
- 2007-12-17 AU AU2007336068A patent/AU2007336068B2/en not_active Ceased
- 2007-12-17 JP JP2009542200A patent/JP5222855B2/ja not_active Expired - Fee Related
- 2007-12-17 CA CA002673359A patent/CA2673359A1/en not_active Abandoned
-
2009
- 2009-05-27 IL IL198989A patent/IL198989A0/en unknown
- 2009-05-27 IL IL198990A patent/IL198990A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008075019A1 (en) | 2008-06-26 |
| AU2007336068B2 (en) | 2013-05-02 |
| US8148404B2 (en) | 2012-04-03 |
| IL198989A0 (en) | 2010-02-17 |
| AU2007336068A1 (en) | 2008-06-26 |
| EA200900838A1 (ru) | 2010-02-26 |
| EP2121617B1 (en) | 2014-01-22 |
| NZ578063A (en) | 2011-09-30 |
| CN103145620A (zh) | 2013-06-12 |
| JP2010513435A (ja) | 2010-04-30 |
| CA2673177A1 (en) | 2008-06-26 |
| US8124634B2 (en) | 2012-02-28 |
| CA2673359A1 (en) | 2008-06-26 |
| WO2008075012A1 (en) | 2008-06-26 |
| JP5437812B2 (ja) | 2014-03-12 |
| EP2121659B1 (en) | 2013-05-15 |
| JP2010513438A (ja) | 2010-04-30 |
| EP2121659A1 (en) | 2009-11-25 |
| US20100010061A1 (en) | 2010-01-14 |
| EA017170B1 (ru) | 2012-10-30 |
| US20100144701A1 (en) | 2010-06-10 |
| BRPI0720732A2 (pt) | 2014-04-08 |
| IL198990A0 (en) | 2010-02-17 |
| EP2121617A1 (en) | 2009-11-25 |
| AU2007336061A1 (en) | 2008-06-26 |
| AU2007336061B2 (en) | 2013-06-27 |
| WO2008075013A1 (en) | 2008-06-26 |
| JP5222855B2 (ja) | 2013-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006214A (es) | Moduladores del receptor cb1. | |
| HRP20090235B1 (hr) | Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d | |
| MY157410A (en) | Microbiocidal heterocycles | |
| NO20063866L (no) | 1,3,5-trisubstituerte 4,5-di hydro-1 H-pyrazolderivater med CB1-antagonistisk aktivitet. | |
| MX2010006109A (es) | Moduladores de receptores de canabinoides. | |
| MX2009013591A (es) | Proceso para la preparacion de pirazoles. | |
| PH12014500559B1 (en) | Plant disease control composition and its use | |
| PH12014500775A1 (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| DE602005016775D1 (de) | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion | |
| WO2008068424A8 (fr) | Derives de 2, 5-dihydro-3h-pyrazolo [4, 3-c] pyridazin-3-one substitues, leur preparation et leur utilisation comme ligands des recepteurs cb1 des cannabinoides | |
| MX2010007019A (es) | Compuestos de bencimidazol. | |
| NZ597810A (en) | Indole derivative or pharmacologically acceptable salt thereof, as ep1 receptor antagonists for the treatment of lower urinary tract dysfunction | |
| MX2010001566A (es) | Derivado de aminopirazolamida. | |
| MX2009013115A (es) | Derivados de prolinamida como antagonistas de nk3. | |
| WO2006136859A3 (en) | Indoli zine derivatives and their use as crth2 antagonists | |
| MX2009012471A (es) | Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6. | |
| MX2011009700A (es) | Derivado de amida. | |
| MX2009008324A (es) | Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6. | |
| WO2008136388A1 (ja) | アミド化合物ならびにその植物病害防除用途 | |
| HRP20110780T1 (hr) | Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6 | |
| MX2007010572A (es) | Compuestos de cinolina y su uso como moduladores de receptor x de higado. | |
| TN2013000546A1 (en) | Microbiocidal heterocycles | |
| WO2009153569A3 (en) | Cb1 receptor modulators | |
| PE20070366A1 (es) | Compuestos derivados de pirazolina sustituidos como moduladores de los receptores de cannabinoides 1 (cb1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |